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A subgroup of pediatric acute T-lymphoblastic leukemia (T-ALL) was characterized by a gene expression proﬁle comparable
to that of early T-cell precursors (ETPs) with a highly unfavorable outcome. We have investigated clinical and molecular
characteristics of the ETP-ALL subgroup in adult T-ALL. As ETP-ALL represents a subgroup of early T-ALL we particularly focused
on this cohort and identiﬁed 178 adult patients enrolled in the German Acute Lymphoblastic Leukemia Multicenter studies
(05/93--07/03). Of these, 32% (57/178) were classiﬁed as ETP-ALL based on their characteristic immunophenotype. The outcome
of adults with ETP-ALL was poor with an overall survival of only 35% at 10 years, comparable to the inferior outcome of early
T-ALL with 38%. The molecular characterization of adult ETP-ALL revealed distinct alterations with overexpression of stem
cell-related genes (BAALC, IGFBP7, MN1, WT1). Interestingly, we found a low rate of NOTCH1 mutations and no FBXW7 mutations
in adult ETP-ALL. In contrast, FLT3 mutations, rare in the overall cohort of T-ALL, were very frequent and nearly exclusively
found in ETP-ALL characterized by a speciﬁc immunophenotype. These molecular characteristics provide biologic insights and
implications with respect to innovative treatment strategies (for example, tyrosine kinase inhibitors) for this high-risk subgroup
of adult ETP-ALL.
Blood Cancer Journal (2012) 2, e55; doi:10.1038/bcj.2011.49; published online 27 January 2012
Keywords: acute lymphoblastic leukemia; ETP-ALL; T-ALL; molecular characteristics; FLT3; NOTCH1
INTRODUCTION
Early T-cell precursors (ETPs) are intrathymic c-Kit
hi double-
negative (DN)1 cells, which contribute to the development of
T-lymphocytes.
1,2 These cells represent immature progenitors that
have recently immigrated from the bone marrow to the thymus. In
addition to their T-lymphoid potential, they carry a natural killer,
dendritic, and remarkably, myeloid cell differentiation potential.
3
Recently, a small subgroup of pediatric acute T-lymphoblastic
leukemia (T-ALL) was described showing a gene expression proﬁle
closely linked to the expression signature of ETPs.
4,5 This subtype,
termed ETP-ALL, is characterized by a speciﬁc immunophenotype:
CD1a
 , CD8
 , CD5
weak and expression of stem cell or myeloid
markers. Moreover, ETP-ALLs are distinguished by high expression
of oncogenic transcription factors, including genes involved in the
pathogenesis of T-ALL like LMO1, LYL1 and ERG. Pediatric patients
with ETP-ALL showed a highly unfavorable outcome compared
with typical T-ALL.
4 On the basis of these results, the
Italian national study Associazione Italiana Ematologia Oncologia
Pediatrica (AIEOP) and St-Jude Children’s hospital proposed
modiﬁcations in their treatment schedules for children with
ETP-ALL towards a more intensive regime including allogeneic
stem cell transplantation (alloSCT).
4 Up to date, the existence of a
subtype with an ETP gene expression signature in adult patients
has not yet been investigated.
Although several molecular risk factors with prognostic and
potential therapeutic implications have been identiﬁed, such as
mutations (NOTCH1) or aberrant expression (BAALC, ERG, TLX1,
TLX3),
6 there is still a need for more precise molecular risk
stratiﬁcations to guide adapted treatment strategies. Although
some study groups utilize an initial leukocyte count above
100000/nl as an adverse prognostic factor, the German Multi-
center Study Group for Adult ALL (GMALL) applies risk stratiﬁca-
tion for T-ALL based on the immunophenotype.
7 On the basis of
the results of earlier study protocols, early (sCD3
 , CD1a
 ) T-ALL is
regarded as a high-risk subgroup and alloSCT is recommended in
ﬁrst complete remission (CR).
7 Therefore, patients with ETP-ALL,
being exclusively found in the subgroup of early T-ALL, are already
assigned towards alloSCT within the GMALL strategy. However,
the multilineage ability of normal ETPs and the stem cell-like
features of oncogenetically transformed ETP-ALL may translate
in primary resistance to conventional chemotherapy. Thus, a
standard protocol for lymphoblastic diseases might be insufﬁcient
and new molecular targets are warranted for speciﬁc targeted
therapy in order to improve overall survival (OS) in this high-risk
disease.
Although the implementation of speciﬁc targeted therapies
have already been applied to high-risk B-ALL characterized by
BCR-ABL and CRLF2/JAK activation, alterations of the tyrosine
kinase pathway have only been identiﬁed in rare cases of T-ALL
presenting with rearrangements NUP214-ABL1 and STRN3-JAK2.
8
In this study, we have investigated the existence of ETP-ALL
among adult patients and, in particular, assessed their clinical as
well as molecular characteristics. We further explored the ETP-ALL
as a molecular distinct subgroup of T-ALL and identiﬁed a high
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direct to innovative treatment strategies for this distinct T-ALL
subgroup.
PATIENTS AND METHODS
Patients and treatment
We analyzed 178 patients classiﬁed as early T-ALL in the GMALL study trials
between 1993 and 2008. The GMALL protocols include a combination of
chemotherapy, radiation, and with the protocol 06/99, alloSCT was
implemented for high-risk T-ALL-patients. Details of the protocols were
previously described.
9 All patients gave written informed consent to
participate in the study according to the Declaration of Helsinki.
10
This study was approved by the ethics board of the Johann Wolfgang
Goethe-Universita ¨t Frankfurt am Main, Germany. In the GMALL study,
immunophenotyping was centrally performed in the GMALL reference
laboratory at the Charite ´ University Hospital, Berlin. Immunophenotyping
and subtype assignment was carried out as previously described.
11- -13
High-risk T-ALL was deﬁned by an immunophenotype of an early
(sCD3
 , CD1
 ) or mature (sCD3
þ, CD1
 ) T-ALL. ETP-ALL was deﬁned as
a subgroup within early T-ALL with the following immunophenotype:
CD1a
 , CD8
 , CD5
weak with expression of stem cell (CD34, HLA-DR, CD117)
and/or coexpression of myeloid antigens (CD13, CD33, CD65s). Absence,
positivity and weak expression of antigens were deﬁned according to the
deﬁnitions in pediatric patients.
4
Nucleic acid preparation and molecular characterization
For patients with sufﬁcient material available, pretreatment bone marrow
samples were used for DNA and total RNA extraction using TRIzol (Life
Technologies, Grand Island, NY, USA) according to the manufacturer’s
protocol with minor modiﬁcations. Complementary DNA was synthesized
using 500ng of total RNA and avian myeloblastosis virus reverse
transcriptase (RT-AMV; Roche, Mannheim, Germany) in the presence of
RNase inhibitor (RNasin; Roche).
Molecular diagnostic examinations were available from in total 297
T-ALL patients (including all immunophenotypical subgroups) from the
two GMALL studies 06/99 and 07/03. As far as material was available,
samples were investigated by comparative real-time PCR (RT-PCR) for
expression of ﬁve genes (BAALC, ERG, IGFBP7, WT1 and MN1). mRNA
expression levels for WT1,
14 BAALC
13 and ERG
13 were determined by
RT-PCR as previously described. The primers for IGFBP7 are available on
request. MN1-primers were designed as reported.
15 GUS was used as a
housekeeping gene with the exception of ABL in the RT-PCR for MN1.
In 142 patient samples, the NOTCH1 mutation status was identiﬁed by
sequencing of PCR-ampliﬁed products.
16,17 For the FBWX7 mutation status,
exons 8 and 9 were sequenced in 121 patients samples as previously
described.
18 WT1 mutations analyses was performed as recently
reported.
14 FLT3 mutations (internal tandem duplications (ITD)/tyrosine
kinase domain (TKD)) were analyzed using a commercially available FLT3
mutation assay (InVivoScribe Technologies, San Diego, CA, USA) in 123
T-ALL patients. Because of lack of sufﬁcient material, not all samples could
be analyzed. No signiﬁcant differences regarding immunophenotype,
age or sex were found in the different subsets of patients analyzed in the
different experiments.
Statistical analyses
Differences in the clinical characteristics as well as response to induction
therapy were tested by the Pearson w
2-test. For OS and duration of
remission in the different subgroups, Kaplan- -Meier curves were created
and compared by the log-rank test. OS was calculated from the time-point
of study entry to the time-point of death or latest follow-up (censored).
Remission duration was calculated in CR patients from the time-point of
ﬁrst CR until relapse or last follow-up. Stem cell transplantation in ﬁrst CR,
death in CR, withdrawal and continuous remission were censored at the
respective dates.
The statistical difference of gene expression between two independent
groups was tested by the nonparametric Mann- -Whitney U-test. Differences
in the mutation rate were analyzed by the Pearson w
2-test. For all tests,
a P-value o0.05 (two-sided) was considered to indicate a signiﬁcant
difference. All calculations were performed using the SPSS software
version 17 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism software
version 5 (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
Patients’ characteristics and clinical outcome
We ﬁrst restricted our analysis to 178 patients diagnosed with an
immunophenotype of early T-ALL who were enrolled in the
GMALL trials (05/93, 06/99, 07/03) between 1993 and 2008. This
cohort of early T-ALL patients represents 23% of all patients with
T-ALL enrolled in the mentioned studies.
7 All samples were clearly
positive for cytoplasmic CD3. Applying the immunophenotypic
ETP-ALL proﬁle (CD1a
 , CD8
 , CD5
weak with expression of stem
cell or myeloid markers), 57 patients (32% of early T-ALL) were
classiﬁed as ETP-ALL, corresponding to 7.4% of all adult T-ALL
patients. Notably, none of the early T-ALL cases fulﬁlled the
EGIL criteria for biphenotypic leukemia.
The clinical characteristics were similar between the group of
ETP-ALL and non-ETP early T-ALL regarding sex, age, white blood
cell count, and central nervous system involvement (Table 1).
However, a lower frequency of patients with a mediastinal mass at
diagnosis was found among patients with ETP-ALL compared with
those with non-ETP early T-ALL (28% vs 47%; P¼0.02). Patients of
both groups were treated equally in the three GMALL trials and
the rate of patients receiving an alloSCT in ﬁrst CR did not differ
between ETP-ALL and non-ETP early T-ALL (59% vs 60%,
respectively). Slightly fewer patients with ETP-ALL achieved a CR
after induction therapy (42 of 53 patients; 79%) compared
with patients with non-ETP early T-ALL (93 of 113 patients; 82%;
Table 1. Characteristics of patients enrolled in the three GMALL study
trials 05/93, 06/99 and 07/03 with the diagnosis of early T-ALL
ETP-ALL
(n¼57) (%)
Non-ETP
early T-ALL
(n¼121) (%)
P
Sex
Male 47 (82.5) 84 (69.4) 0.07
Female 10 (17.5) 37 (30.6)
Age
15--35 27 (47.4) 68 (56.2) 0.27
36--65 30 (52.6) 53 (43.8)
WBC count (n¼163)
o30/nl 32 (62.7) 71 (63.4) 0.94
430/nl 19 (37.3) 41 (36.6)
Mediastinal mass (n¼162)
No 37 (72.5) 59 (53.2) 0.02
Yes 14 (27.5) 52 (46.8)
CNS involvement (n¼150)
No 42 (91.3) 100 (96.2) 0.22
Yes 4 (8.7) 4 (3.8)
Response to induction
CR 42 (79.2) 93 (82.3) 0.65
PR/failure 5 (9.4) 12 (11.7)
Death in induction 6 (11.3) 8 (7.8)
Abbreviations: CNS, central nervous system; CR, complete remission;
ETP-ALL, early T-cell precursors-acute lymphoblastic leukemia; PR, partial
remission; T-ALL, acute T-lymphoblastic leukemia; WBC, white blood cell.
Comparison between ETP-ALL and early T-ALL with a non-ETP
immunophenotype.
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therapy, 6 in the group of ETP-ALL, 8 in the group of non-ETP early
T-ALL. Regarding all high-risk early T-ALL patients in the three
study trials, the probability of survival at 10 years was comparably
poor in patients with ETP-ALL and non-ETP early T-ALL (35% vs
38%, Figure 1a). In patients with early T-ALL, more patients
remained in CR in the group of non-ETP early T-ALL than in the
group of ETP-ALL (57% vs 46%, n.s., Figure 1b) with a follow-up of
9 years.
Aberrant gene expression in ETP-ALL
To further characterize the ETP-ALL on the molecular level, we
analyzed the expression of selected genes known to be involved
in the pathogenesis and with prognostic implications in T-ALL in
samples with sufﬁcient material. We ﬁrst compared ETP-ALL, as a
new subgroup, to all remaining T-ALL subtypes including thymic,
mature and early T-ALL. As previously described, high expression
of BAALC and ERG predicted an unfavorable outcome in adults
with T-ALL.
10,13 Quantitative RT-PCR assays revealed that BAALC
was 5.34-fold highly expressed in ETP-ALL compared with all
remaining T-ALL (Po0.001, Figure 2a). ERG only showed a slight,
however not signiﬁcantly elevated expression (1.33-fold, P¼0.12,
Figure 2a). IGFBP7 is a stem cell-associated gene, which is highly
associated with BAALC and overexpressed in early T-ALL
19 and
among the genes highly overexpressed in pediatric ETP-ALL.
4
Similar to BAALC, it was signiﬁcantly upregulated in ETP-ALL
(3.53-fold, P¼0.003, Figure 2a). The gene WT1 was of interest as it
is widely overexpressed in AML
20 and as its overexpression is
associated with a poor outcome in thymic T-ALL patients.
14
Interestingly, we found a signiﬁcantly elevated WT1 expression in
ETP-ALL (4.33-fold, P¼0.04, Figure 2a). Because of the myeloid
potential of ETPs and the frequent coexpression of myeloid
surface antigens in ETP-ALL lymphoblasts, we further investigated
the expression of MN1 as its overexpression was found to be
associated with a shorter survival in AML without karyotypic
abnormalities.
15,21 Here, we show that MN1 was signiﬁcantly
overexpressed in the group of ETP-ALL compared with all
remaining T-ALL patients (2.86-fold, Po0.001; Figure 2a).
Although these ﬁve genes were also upregulated in early T-ALL
compared with mature or thymic T-ALL, WT1, BAALC, IGFBP7 and
MN1 showed an even higher expression in the ETP-ALL group
compared with the remaining group of non-ETP early T-ALL
(Figure 2b).
Mutational analyses in ETP-ALL
Differences in the mutation status of candidate genes between
ETP-ALL and non-ETP-ALL cases were explored (Table 2). The most
frequent pathogenetic mutational event in T-ALL are NOTCH1
mutations occurring in approximately 50--70% of the cases,
predominantly in thymic T-ALL
22- -24 Although NOTCH1 mutations
have been associated with an initial good response in some
studies, the prognostic impact of NOTCH1 mutations in T-ALL
remains controversial.
8,25- -29 In 142 adult T-ALL samples analyzed,
we have found a low rate of NOTCH1 mutations in the immature
subgroup of ETP-ALL (n¼1/14, 7.1%), whereas NOTCH1 mutations
were frequent (60.9%) in non-ETP T-ALL (n¼78/128, P¼0.001,
Table 2). Similar ﬁndings were observed for the tumor-suppressor
gene FBXW7 involved in NOTCH1 signaling: no FBXW7 mutations
were found in the 14 ETP-ALL samples analyzed.
Mutations in the WT1 gene were reported in about 8% of all
T-ALL patients.
14 We did not observe a signiﬁcant difference in the
frequency of WT1 mutations between ETP-ALL and the remaining
T-ALL (Table 2).
Although FLT3 mutations are frequent in AML (B30%) and have
important prognostic and therapeutic implications, mutations for
FLT3 as ITD or in the TKD in T-ALL are very rare.
30- -32 Interestingly,
in our cohort we identiﬁed seven patients with mutations of
FLT3 that were exclusive in the cohort of early T-ALL patients and
predominantly found in the subgroup of ETP-ALL patients. Five
cases (4.5%) had mutations in the tyrosine kinase domain of FLT3
(D835), four of them were in the group of ETP-ALL (Po0.001).
Another case with an FLT3 mutation was assigned to early T-ALL,
but the immunophenotype did not fulﬁl the criteria of an ETP-ALL
due to a weak CD8 expression. This case also showed surface
expression of the myeloid antigens CD13 and the stem cell
markers CD34 and CD117. ITD mutations of FLT3 were only found
in two of the 123 cases, both being in the group of ETP-ALL
(Po0.001). In total, six of seven FLT3-mutations found were in the
group of ETP-ALL, displaying a frequency of 37.5% within this
subgroup. Interestingly, FLT3-mutated ETP-ALL patients showed
different clinical and molecular characteristics compared with FLT3
wild-type ETP-ALL patients. The seven patients with an FLT3
mutation had a median age of 40 years and an initial white blood
cell of 3800/ml. Five FLT3-mutated ETP-ALL patients were
transplanted in ﬁrst remission and the median OS was 31.3
months with six patients being still alive. Remarkably, patients
with a FLT3 mutation showed a distinct immunophenotype
with positivity for CD117 (7/7 patients), CD34 (6/7 patients),
CD13 (7/7 patients), and CD2 (7/7 patients). In contrast, ETP-ALL
patients with a FLT3 wild-type status had more often positivity for
CD5 (7/10 patients) and CD33 (6/10 patients).
DISCUSSION
In T-ALL, outcome has been slightly improved in the past decades,
mainly because of the implementation of alloSCT for speciﬁc
subgroups.
7,33 However, long-term OS only reaches rates of
30--60% depending on prognostic factors and subgroups.
34
Further improvement remains warranted and may be achieved
by enhanced risk stratiﬁcation and development of novel
Figure 1. Kaplan--Meier analyses for OS (a) and remission duration
(b) for patients with ETP-ALL and early T-ALL with a non-ETP
immunophenotype. Patients were enrolled in the GMALL study trials
GMALL 05/93, GMALL 06/99 and GMALL 07/03.
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ETP-ALL (%) Non-ETP
T-ALL (%)
P ETP-ALL (%) Non-ETP
early T-ALL (%)
P
(a) (b)
FBXW7 (n¼128) FBXW7 (n¼50)
wt 14 (100) 98 (86) 0.13 wt 14 (100) 27 (100) - --
mut 0 (0) 16 (14) mut 0 (0) 0 (0)
NOTCH1 (n¼142) NOTCH1 (n¼50)
wt 13 (92.9) 50 (39.1) o0.001 wt 13 (92.9) 16 (47.1) 0.003
mut 1 (7.1) 78 (60.9) mut 1 (7.1) 18 (52.9)
FLT3 (ITD) (n¼123) FLT3 (ITD) (n¼40)
wt 14 (87.5) 107 (100) o0.001 wt 14 (75) 24 (100) 0.08
mut 2 (12.5) 0 (0) mut 2 (25) 0 (0)
FLT3 (D835) (n¼116) FLT3 (D835) (n¼40)
wt 12 (75) 99 (99) o0.001 wt 12 (75) 23 (95.8) 0.05
mut 4 (25) 1 (1) mut 4 (25) 1 (4.2)
WT1 (n¼227) WT1 (n¼63)
wt 12 (80) 196 (92.5) 0.09 wt 12 (80) 42 (87.5) 0.47
mut 3 (20) 16 (7.5) mut 3 (20) 6 (12.5)
Abbreviations: ETP-ALL, early T-cell precursors-acute lymphoblastic leukemia; ITD, internal tandem duplications; mut, mutant; T-ALL, acute T-lymphoblastic
leukemia; wt, wild type. Non-ETP T-ALL includes all thymic, mature and early T-ALL with a non-ETP immunophenotype. Analysis was performed as far
as sufﬁcient material was available.
Figure 2. Expression of genes known to be correlated with outcome in T-ALL and AML. Analysis of samples with sufﬁcient RNA was carried
out by RT-PCR. For each entity the median expression is shown by a horizontal bar with the s.e. of the mean. (a) Comparison between
ETP-ALL and the remaining non-ETP T-ALL. (b) Expression in the different immunophenotype-deﬁned subgroups of T-ALL. Early T-ALL refers
to non-ETP early T-ALL.
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therapies.
We characterized a new subgroup of adult patients with T-ALL
(7.4%) with an immunophenotype of pediatric ETP-ALL.
4 The
frequency of ETP-ALL in adult T-ALL was slightly lower than ﬁrst
reported for pediatric ETP-ALL, but in the range of a recent report
from the Children’s Oncology Group (COG).
35 Similar to the
pediatric study, there were no differences in the clinical
characteristics between the groups of ETP-ALL and early T-ALL
with the exception of a lower frequency of a mediastinal mass in
ETP-ALL.
Although many features are in common, there are relevant
differences between adult and pediatric T-ALL, especially with
respect to treatment. There are no immunophenotype-deﬁned
subgroups that are currently used for risk stratiﬁcation in larger
pediatric T-ALL trials.
36,37 In contrast, early T-ALL has been
recognized as an immunophenotype-deﬁned subtype with
poor prognosis in adult T-ALL
33, and since 1999, the GMALL
study group in accordance with other study groups
38 deﬁnes early
T-ALL as high-risk T-ALL
39,40 with consecutive recommendation for
alloSCT. This led to an improvement in the OS at 5 years of 40%.
7
Therefore, the ETP-ALL as a subgroup of early T-ALL is already
regarded as a T-ALL subgroup with poor prognosis requiring
intensiﬁed therapy. In agreement with pediatric ETP-ALL, adult
ETP-ALL showed an unfavorable outcome in our analysis similar to
early T-ALL.
7 Interestingly, a high overlap to groups with an
unfavorable prognosis, characterized by negativity of CD1 and
positivity for CD33, and the group of early T-ALL is evident.
33
These T-ALLs overrepresented in early T-ALL are speciﬁcally
contained in the subgroup of ETP-ALL.
To unravel the underlying molecular alterations of ETP-ALL as a
speciﬁc T-ALL subgroup, we studied the expression of candidate
genes reported to be of prognostic impact. Out of these, the
expression of stem cell-associated genes (BAALC and IGFBP7) and
genes known to be of prognostic signiﬁcance in AML (BAALC, MN1,
WT1) are underlining the immature nature of ETP-ALL. BAALC is
preferentially expressed in the immature T-ALL phenotypes
compared with the remaining T-ALL, and its high expression has
been correlated to a subgroup with poor outcome.
13 Moreover,
T-ALL patients with high BAALC expression frequently showed an
aberrant expression of myeloid markers. High BAALC expression is
also linked to an immature phenotype in AML with normal
cytogenetics,
41 to a more aggressive BCR-ABL-positive acute
lymphoblastic leukemia
42 and is associated with an unfavorable
outcome in B-precursor ALL.
43 This led to the hypothesis that
BAALC is a marker for acute leukemia derived from early
progenitors with multi-lineage potential. Recently, IGFBP7 was
identiﬁed as a lineage-independent BAALC co-expressed gene
with prognostic impact and a potential link to BAALC.
44 BAALC and
IGFBP7 were also found as highly expressed genes within the
ETP-ALL gene expression signature.
4 In addition, overexpression of
MN1 was recently identiﬁed to be associated with ETP-ALL, and
might also provide an indirect support for the poor prognosis of
ETP-ALL.
45 These ﬁndings are underlined in this work as BAALC,
IGFBP7 and MN1 were upregulated in ETP-ALL, probably originat-
ing from T-cell progenitors retaining myeloid differentiation
potential. This multilineage potential is further strengthened
by the overexpression of the molecular marker WT1 in ETP-ALL,
a gene known to be of unfavorable prognosis in AML as well as in
a subgroup of T-ALL
46- -50 Interestingly, a recent work identiﬁed a
subgroup in adult T-ALL (B10%) with myeloid characteristics
using gene expression proﬁling with limited clinical data and no
mutations or mutational events.
51 Up to which degree this group
overlaps with ETP-ALL has to be determined in further studies.
In addition to these particular gene expression patterns, we
found a clear difference in mutation events of genes known to be
involved in the pathogenesis of T-ALL or AML. The high rate of
NOTCH1 mutations in T-ALL with a frequency of about
50%
26,27,52,53 makes the NOTCH1 signaling pathway an interesting
candidate for targeted therapies by the implementation of
a ˜-secretase inhibitors.
54,55 Whether NOTCH1 mutations could
initiate leukemia alone
56- -58 or are mainly secondary effects in
human T-ALL
59 is discussed controversially.
60,61 Interestingly, only
one NOTCH1 mutation was found in the small group of analyzed
ETP-ALL, thus demonstrating a clear pathogenetic difference to
non-ETP T-ALL (61% NOTCH1 mutations) as ETP-ALL is yet the only
subgroup that lacks NOTCH1 mutations. Additionally, in the group
of ETP-ALL, mutations of the less frequent mutated tumor
suppressor gene FBXW7 were not found, again supporting a
different pathogenesis for the group of ETP-ALL, likely indepen-
dent from the activated NOTCH1 pathway. Therefore, targeted
therapies implementing g-secretase inhibitors would presumably
be less effective in ETP-ALL lacking mutational activated NOTCH1
signaling.
Most remarkably, we found a high rate of FLT3 mutations in
ETP-ALL with a not yet reported high incidence of 37.5%, albeit in
a small cohort (16 patients with ETP-ALL). Thus, with respect to the
FLT3, NOTCH1/FBXW7 and WT1 mutation status, ETP-ALL shows a
clearly different mutational proﬁle compared with non-ETP T-ALL
(Figure 3) indicating a distinct biological entity.
With respect to FLT3 mutations, we found in contrast to AML
more frequently TKD than ITD mutations. This ﬁnding is in line
with data from a murine bone marrow transplantation model,
where mice that received a transplant of FLT3-ITD-transduced
bone marrow cells developed myeloproliferative diseases,
whereas a transplant of FLT3-TKD-transduced bone marrow cells
induced lymphoid disorders.
62 More recently, it was shown that a
subset of common myeloid progenitors (FLT3
þCD150
 ) has the
potential to develop into T cells.
63 Although FLT3 mutations in
T-ALL are generally very rare (1--3%),
30 FLT3 mutations were
proposed to be frequently found in CD117þ T-ALL patients,
32,64
an antigen frequently expressed on ETP-ALL lymphoblasts.
Although FLT3 mutation screening is clinically not indicated in
unselected newly diagnosed T-ALL, ETP-ALL as a distinct subgroup
Figure 3. Distribution of mutations (FBXW7, NOTCH1, FLT3, WT1) in percent in ETP-ALL (n¼16 on the left) and non-ETP T-ALL (n¼212 on the
right). Not all T-ALL samples tested for WT1 were also tested for NOTCH1 and FLT3 mutations in the cohort of non-ETP T-ALL.
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for FLT3 mutations. Moreover, these ﬁndings result in enlarged
treatment options for this group with poor outcome
65 including
tyrosine kinase inhibitors (TKI), which are currently investigated in
trials for the treatment in AML. Importantly, similar to myeloid
cells, T-ALL cell lines transfected with an FLT3 ITD expression
construct showed particular sensitivity to tyrosine kinase inhibi-
tion further justifying the use of TKI in FLT3-mutated ETP-ALL
(data not shown). As ETP-ALL in pediatric patients is associated
with high minimal residual disease levels after induction
therapy,
32 the use of TKI may be efﬁcient to lower the leukemic
blast burden before alloSCT in minimal residual disease-positive
patients. Furthermore, TKI could be implemented in the treatment
of a relapse after alloSCT.
We identiﬁed the speciﬁc subgroup of ETP-ALL based on the
deﬁnition of a certain immunophenotype in adult T-ALL. Overall,
the outcome of ETP-ALL is comparably poor to early T-ALL.
Therefore, intensiﬁed treatment protocols including alloSCT, as
already implemented in the therapy of adult T-ALL, seems
warranted for these high-risk patients. Moreover, as ETP-ALL has
distinct molecular features with a high rate of FLT3 mutations,
these data point to new targeted therapy options including TKI for
these high-risk T-ALL patients.
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